Comparison of Adverse-Event Profiles of Intravenous Low-Molecular-Weight Iron Dextran and Iron Sucrose in Peritoneal Dialysis Patients

Basit Öğe Kaydı
dc.contributor.authorSolak, Yalcin
dc.contributor.authorAtalay, Huseyin
dc.contributor.authorGuney, Ibrahim
dc.contributor.authorTurkmen, Kultigin
dc.contributor.authorKaya, Emine
dc.contributor.authorTurk, Suleyman
dc.date.accessioned2020-03-26T18:13:58Z
dc.date.available2020-03-26T18:13:58Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: Both erythropoiesis-stimulating agents and iron treatments are underutilized in peritoneal dialysis (PD) patients. Studies to evaluate safety profiles of various intravenous iron preparations are limited in PD patients compared to hemodialysis. No study in the literature compared safety of low-molecular-weight iron dextran (LMW-ID) with that of iron sucrose in PD patients. We aimed to compare adverse-effect profiles of LMW-ID and iron sucrose with varying dosing schedules in PD patients with a hope to foster use of parenteral iron solutions in PD patients. Methods: We retrospectively reviewed patient charts and included patients who were administered iron sucrose or LMW-ID parenterally. Sociodemographic characteristics, clinical features, and pertinent laboratory data were collected. Adverse events which were deemed to be related to infusion of parenteral iron were recorded. We double-checked both physician records and nursing documents for observed adverse events. Results: A total of 167 chronic PD patients were included in the study, and 92 patients were administered LMW-ID, whereas 75 patients were administered iron sucrose. Only one adverse event occurred in a patient who was administered 500 mg iron sucrose in a single infusion. Conclusions: This study showed the comparable safety of LMW-ID in varying doses over that of iron sucrose in PD patients.en_US
dc.identifier.doi10.3109/0886022X.2011.560404en_US
dc.identifier.endpage311en_US
dc.identifier.issn0886-022Xen_US
dc.identifier.issue3en_US
dc.identifier.pmid21401355en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage307en_US
dc.identifier.urihttps://dx.doi.org/10.3109/0886022X.2011.560404
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26250
dc.identifier.volume33en_US
dc.identifier.wosWOS:000288323700009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherINFORMA HEALTHCAREen_US
dc.relation.ispartofRENAL FAILUREen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAdverse eventen_US
dc.subjectiron sucroseen_US
dc.subjectlow-molecular-weight iron dextranen_US
dc.subjectperitoneal dialysisen_US
dc.subjectsafetyen_US
dc.titleComparison of Adverse-Event Profiles of Intravenous Low-Molecular-Weight Iron Dextran and Iron Sucrose in Peritoneal Dialysis Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu